News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Theraclone Sciences, Inc. Announces Identification Of New Vulnerable Site On HIV Using Antibodies Discovered With Theraclone Technology


4/25/2014 7:50:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced the publication of data in the May issue of Immunity regarding antibodies with significant potency and breadth against human immunodeficiency virus (HIV). The study, titled “Broadly neutralizing HIV antibodies define a novel glycan-dependent epitope on the pre-fusion conformation of gp41 on cleaved envelope trimers,” describes a set of recently isolated human monoclonal antibodies that target a region of HIV that differs from the epitopes recognized by broadly neutralizing antibodies (bNAbs) discovered previously.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES